PARP Inhibitors in Pancreatic Cancer: Experts Discuss Importance of Testing for Biomarkers Along With Current Treatment Landscape - a podcast by Clinical Care Options

In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:

• Importance of germline and somatic testing
• Adverse events associated with PARP inhibitors
• Maintenance therapy in pancreatic cancer

Presenters:

Philip Agop Philip, MD, PhD, FRCP
Professor
School of Medicine
Wayne State University
Leader, Gastrointestinal Multidisciplinary Team
Department of Oncology
Karmanos Cancer Institute
Detroit, Michigan

Elena Gabriela Chiorean, MD
Professor of Medicine
Division of Medical Oncology
Department of Medicine
University of Washington
Member
Fred Hutchinson Cancer Research
Seattle, Washington

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program:
https://bit.ly/3jEehCc

Link to associated downloadable PDF:
https://bit.ly/3nSfTcR

Further episodes of CCO Oncology Podcast

Further podcasts by Clinical Care Options

Website of Clinical Care Options